Conference call and webcast scheduled for 8:30 a.m. Eastern Time Today, Thursday, August 14, 2025 NEW YORK, Aug. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced...
Related Questions
How did Q2 2025 revenue and net loss compare to consensus estimates?
What is the updated cash runway given the latest cash balance and burn rate?
Did the company provide revised guidance for upcoming quarters or FY 2025?
Are there any new partnership or licensing agreements disclosed in the update?
What are the latest developments and expected trial timelines for the lead stem cell therapy programs?
How does BrainStorm's current valuation metrics compare to peers in the neurodegenerative space?
Did the company address any regulatory milestones or FDA interactions that could affect future milestones?
What is the expected short‑term impact of this corporate update on share price volatility?
Are there any changes in capital structure, such as share issuances, convertible notes, or debt financing, that investors should note?
How might the sentiment score of 20 influence market perception and potential price movement?
What key takeaways from the conference call could affect the stock's momentum?